(Q35826806)

English

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

scientific article published in September 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis (English)

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Vivien Chan

1

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Bruce G Charles

2

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Susan E Tett

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

British Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

60

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

257-264

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

Clinical pharmacokinetics of leflunomide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

Leflunomide Aventis Pharma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

Mechanism of action of leflunomide in rheumatoid arthritis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

Measuring outcomes in primary care: a patient generated measure, MYMOP, compared with the SF-36 health survey

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

A clinical comparison of two pain scales: Correlation, remembering chronic pain and a measure of compliance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

11 July 2018

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

Dose escalation of leflunomide (LEF) to 40 mg once daily in patients with rheumatoid arthritis and insufficient response to standard dose LEF.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

An unusual overdose of leflunomide in a patient with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2125.2005.02415.X

21 January 2018

Learning from pain scales: patient perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

24 September 2018

Pharmacokinetics of leflunomide in Chinese healthy volunteers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1884779

24 September 2018

Comparison of verbal and visual analogue scales for measuring the intensity and unpleasantness of experimental pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/16120064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16120064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression

1 reference

https://pubmed.ncbi.nlm.nih.gov/16120064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16120064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/16120064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2125.2005.02415.X

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

10 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35826806&oldid=1599632792"